Inspira Technologies OXY B.H.N. Ltd. (IINN) has reached a significant milestone with the submission of its INSPIRA ART100 for approval under the Israeli Ministry of Health’s AMAR regulation. This regulatory progress is poised to open doors to new markets, particularly in Southeast Asia and South America, paving the way for remarkable growth opportunities for the company.
AMAR is the Israeli Ministry of Health’s medical device regulation unit. This authority controls medical device licenses and approvals in the Southeast Asia and South American markets.
Exploring the Development
The AMAR submission marks a strategic move by Inspira Technologies, positioning it to target global markets with its innovative Augmented Respiration Technology (INSPIRA ART). This technology, designed to treat patients without mechanical ventilation while awake, represents a radical advancement in life support systems.
Inspira Technologies has emphasized the support from local key opinion leaders for the INSPIRA ART (Gen 2) device currently under development. This upcoming device promises advanced blood oxygenation capabilities, real-time monitoring, and personalized oxygenation control tailored to individual patient needs.
Strategic Significance
The integration of adaptive technology in the INSPIRA ART (Gen 2) device is expected to revolutionize patient care by reducing complications associated with traditional ventilation methods, shortening hospital stays, and potentially saving lives. This breakthrough underscores Inspira Technologies’ commitment to advancing medical technology and improving patient outcomes on a global scale.
Expanding Market Opportunities
According to a Mordor Intelligence report, the Global Respiratory Devices Market is on a steady growth trajectory, estimated at $26.73 billion in 2024 and projected to reach $35.58 billion by 2029, with a CAGR of 5.89%. Despite market fluctuations due to the initial impact of the COVID-19 pandemic, government initiatives and strategic developments have bolstered growth. Rising respiratory disorders like COPD and asthma, along with technological advancements, especially in homecare settings, are driving market expansion.
Financial Performance
Over the past year, Inspira Technologies’ shares surged 48.1%, outperforming the industry’s 11.2% increase.
Zacks Rank and Notable Picks
Inspira Technologies currently holds a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space include Stryker Corporation (SYK), Cencora, Inc. (COR), and Cardinal Health (CAH). Stryker, ranked #2, reported strong financials, with earnings exceeding estimates consistently.
